Unsolved problems and future perspectives of hepatitis B virus vaccination

Kazuto Tajiri, Yukihiro Shimizu

Kazuto Tajiri, Department of Gastroenterology, Toyama University Hospital, Toyama 930-0194, Japan
Yukihiro Shimizu, Gastroenterology Center, Nanto Municipal Hospital, Toyama 932-0211, Japan

Author contributions: Tajiri K and Shimizu Y equally wrote the manuscript.

Conflict-of-interest: The authors have no conflicts of interest.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Yukihiro Shimizu, MD, PhD, Gastroenterology Center, Nanto Municipal Hospital, 938 Inami, Toyama 932-0211, Japan. rsf14240@nifty.com
Telephone: +81-763-821475

Received: January 26, 2015
Peer-review started: January 27, 2015
First decision: March 10, 2015
Revised: March 23, 2015
Accepted: May 4, 2015
Article in press: May 4, 2015
Published online: June 21, 2015

Abstract

Hepatitis B virus (HBV) infection is still a serious worldwide problem, and vaccination is the most effective strategy for primary prevention of the infection. Although universal vaccination may be required for total eradication, several countries, including Japan, have not yet adopted universal vaccination programs. Some individuals are non-responders to HBV vaccine and several mechanisms responsible for their poor response have been proposed. To overcome non-response, third generation vaccines with pre-S proteins have been developed. These vaccines have shown better anti-HBs responses and may also be effective in preventing infection by HBV with S mutant. Improvement of vaccine efficacy by intradermal administration, or co-administration with cytokines or adjuvants, may also be effective in non-responders. The necessity, timing and method of booster vaccination in responders with decreased anti-HBs responses, and effective vaccination against S-mutant HBV, are issues requiring resolution in the global prevention of HBV infection.

Key words: Escape mutant; Immunology; Hepatitis B virus vaccination; Non-responder; Universal vaccination

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Hepatitis B virus (HBV) infection is still a serious worldwide problem, and vaccination is most effective for primary prevention of infection. This review summarizes current unsolved issues and future perspectives on vaccination required for global prevention of HBV infection.

INTRODUCTION

About 400 million people worldwide are chronically infected with hepatitis B virus (HBV), with about half being infected perinatally or during early childhood via
vertical and/or horizontal routes\textsuperscript{[1]}. HBV infection can induce acute hepatitis, which may result in fulminant hepatitis, and chronic hepatitis, which may eventually lead to liver cirrhosis and/or hepatocellular carcinoma (HCC)\textsuperscript{[1]}\textsuperscript{[2]}. HBV infection is responsible for 500000 to 1.2 million deaths per year due to chronic hepatitis, cirrhosis, and HCC\textsuperscript{[2]}. As such, it is responsible for 60% to 80% of HCCs worldwide\textsuperscript{[3]}. Treatment with antiviral agents, including nucleotide analogues and interferon, has been effective in some, but not all, patients with chronic HBV. Therefore, prophylactic approaches are essential to prevent viral infection. Many countries have introduced universal prophylactic vaccination programs, and some individuals, especially those who are immunocompromised, are unable to develop anti-HBs antibody following conventional vaccination. Moreover, HBV in vaccinated subjects may develop mutants, allowing them to escape the effects of vaccination. Attempts have been made to improve the immunogenicity of HBV vaccines. This review describes the current status and unresolved issues of HBV vaccination.

### PREVENTION OF HBV INFECTION BY HBV VACCINES

#### Transmission route of HBV

Methods of HBV transmission at an early age include perinatal, vertical from mother to infant, and horizontal from an infected household member to the child\textsuperscript{[4]}. Perinatal infection occurs in 70% to 90% of babies born to HBeAg-positive mothers, and in less than 15% of babies born to HBeAg-negative mothers\textsuperscript{[5,6]}. The risk of vertical transmission was significantly increased by high serum levels of maternal HBV-DNA\textsuperscript{[7]}, and the rate of infection increased from 0% in mothers with serum HBV-DNA $< 5 \log_{10}$ copies/mL to 50% in those with HBV-DNA $\geq 9 \log_{10}$ copies/mL\textsuperscript{[8]}. Moreover, some reports from China have shown that the reductions of serum HBV DNA in the 3\textsuperscript{rd} trimester of HBsAg-positive pregnant women by the administration of hepatitis B immunoglobulin (HBIG)\textsuperscript{[9]} or nucleoside analogue\textsuperscript{[10,11]} significantly decreased the neonatal intrauterine HBV infection. These data suggest that the serum level of HBV DNA in pregnant women is the major determinant in the occurrence of mother-to-infant transmission.

In infected persons, HBV is found not only in blood but in body fluids, including saliva, semen and vaginal secretions, all of which are capable of transmitting the virus. Furthermore, HBV remains viable for 7 d or longer on environmental surfaces at room temperature.

The World Health Organization (WHO) has classified countries into three categories according to the prevalence of chronic HBV carrier: high (8% or greater); intermediate (2%-8%); and low (less than 2%) (Table 1)\textsuperscript{[12]}. In high endemic areas, the life risk of acquiring HBV infection is greater than 60% and most infections are transmitted vertically/perinatally or horizontally during early childhood. In intermediate endemic areas, the life risk of HBV ranges from 20% to 60%, and infections are found in all age groups. In low endemic areas, the life risk is low, especially in normal living environments, and infections occur primarily in adults through sexual or parenteral transmission\textsuperscript{[12]}. Regardless, vaccination should be considered to prevent HBV infection.

### Hepatitis B vaccine

The first plasma-derived HB vaccine, containing highly purified 22 nm HBsAg inactivated by urea, pepsin, formaldehyde, and heat, was introduced in 1982\textsuperscript{[13]}. Subsequently, yeast-derived recombinant HBV vaccines were introduced in the mid-1980s because of the potential risk of blood-borne infection in plasma-derived vaccines\textsuperscript{[14]}. Yeast-derived vaccines were manufactured by cloning the HBV S gene in yeast cells, yielding nonglycosylated HBV small S protein but not the pre-S region\textsuperscript{[15]}. Due to the potential neurotoxicity of the preservative thimerosal, two yeast-derived recombinant thimerosal-free vaccines (Recombivax HB\textsuperscript{®} and Engerix-B\textsuperscript{®}) were developed and have been widely available\textsuperscript{[16]}. The third generation HB vaccines are mammalian cell-derived recombinant vaccines containing the pre-S region. These vaccines may be more immunogenic in a controlled trial\textsuperscript{[17]}, but are not widely available at present.

HB vaccines used for primary prophylaxis have been shown to reduce the risk of infection in most
populations\(^{[18]}\). A combination vaccine (Twinrix\(^{[8]}\)), containing Engerix-B and HAVRIX (hepatitis A vaccine), is also available\(^{[19,20]}\). The HepB3 hepatitis B vaccination program, consisting of a series of three doses, the second administered one month and the third six months after the first dose, resulted in the production of anti-HBs in about 95% of recipients\(^{[21]}\). No significant side effects have been observed, except for pain at the injection site and mild to moderate fever\(^{[22]}\).

Although HBV is transmitted at a high rate by parenteral, percutaneous and sexual contact, a study from the United States showed that vaccination of high-risk groups had little impact on the incidence of HBV infection\(^{[23]}\). In contrast, since perinatal or early postnatal transmission is the primary cause of chronic infections worldwide, the first dose of HB vaccine should be given as soon as possible after birth (< 24 h) even in low-endemic countries. Primary protection regardless of maternal HBsAg status has been recommended\(^{[24]}\).

**Prophylaxis of HBV-related diseases by hepatitis B vaccine**

To prevent HBV infection, the WHO advocated HBV vaccination of all infants in 1992, or universal vaccination (UV). By the end of 2013, UV had been introduced nationwide in 183 countries. In Japan, UV has not yet been introduced, but will be introduced in the near future. Global coverage with HepB3 is estimated at 81% and is as high as 92% in the Western Pacific\(^{[25]}\) (Figure 1). A meta-analysis of randomized controlled trials of HB vaccination of newborns showed that vaccinated infants born to HBV-positive mothers were 3.5-fold less likely to become infected with HBV (RR = 0.28, 95%CI: 0.20-0.40)\(^{[26]}\).

In Taiwan, a high endemic area, UV of all newborns was implemented in 1986, reducing the HBsAg prevalence rate from 9.8% in 1984 to 0.6% in 2004\(^{[27]}\). Furthermore, the prevalence of HCC in childhood decreased from 0.7 per 100000 in 1981-1986 to 0.36 per 100000 in 1990-1994\(^{[28]}\). After 20 years of this program, the risk of HCC has been decreased by 70% in young adults, indicating that HB vaccine was the first vaccine to successfully prevent a major human cancer\(^{[29,26]}\). Furthermore, almost 30 years later, the prevalence of HBV infection was markedly lower, with HBsAg positivity decreasing from 10% to 0.9% and anti-HBc positivity from 28% to 7%\(^{[30]}\). In the Gambia, HBsAg prevalence in childhood decreased from 10% to 0.6% 10 years after UV introduction\(^{[31,32]}\). In Alaska, the prevalence of hepatitis B was decreased to almost zero and the prevalence of chronic hepatitis among children and young adults was also decreased\(^{[33,34]}\). Furthermore, the incidence of HCC in patients under 20 years of age decreased from 3 per 100000 in 1984-1988 to zero in 1995-1999\(^{[33,34]}\). These findings showed that UV can prevent vertical and horizontal transmission of HBV infection, reducing rates of chronic HBV infection, especially in high endemic areas.

In the United States, a low endemic area, the incidence of acute hepatitis B has declined 82%, from 8.5 per 100000 in 1990 to 1.5 per 100000 in 2007\(^{[35]}\). In Malaysia, HBsAg prevalence in children decreased from 1.6% in 1997 to 0.3% in 2003\(^{[36]}\). In Italy, the morbidity of acute hepatitis B in patients aged 15 to 24 years old decreased from 17 per 100000 in 1990 to less than 0.5 per 100000 in 2005\(^{[37,38]}\).

Despite vaccination at birth, however, 5% of babies become HBV carriers\(^{[39-41]}\). The precise mechanism is unclear, but vaccinated individuals, especially in HBV endemic areas, should be carefully monitored for HBV infection.

**UNRESOLVED PROBLEMS IN HB VACCINATION AND RECENT ADVANCES**

**Non-responders to HB vaccine**

**Mechanisms of nonresponse to HB vaccine:** Three conditions have been shown associated with nonresponse to HB vaccine (Table 2). In addition, around 10% of the general population shows poor responses. Antibody response rates decline gradually after age 40 years, with age being a factor determining response to HB vaccine\(^{[42]}\). The mechanism of nonresponse is not fully understood, but several hypotheses have been proposed.

**Human leukocyte antigen**

Because human leukocyte antigen (HLA) alleles are one of the determinants of the repertoire of peptides presented to T cells, HLA alleles are associated with response to HBV vaccine.

A report from eastern Turkey demonstrated that high frequencies of HLA-A11 and HLA-A24 and a low frequency of HLA-CW6 were associated with nonresponse to HB vaccine\(^{[43]}\). Another report from Turkey showed an association between HLA-DR (HLA-DRB1*04X, DRB1*0401X, DRB1*11/13, and DRB1*0401X0201) haplotypes and non-response, whereas Class-I (HLA-B13) was associated with a good response to HB vaccine\(^{[44]}\). A report from Italy showed that the haplotypes HLA-B8, DR3, and DQ2 were associated with nonresponse to HB vaccine, both in patients with celiac disease and healthy subjects\(^{[45]}\). A recent report from Korea showed that B62, DRB1*07 and DRB1*08(-) were significantly associated with poor responses to vaccine\(^{[46]}\). A meta-analysis of the association between HLA alleles and response to HB vaccine in 2308 subjects, including responders, non-responders, and healthy subjects, found that the DRB1 alleles DRB1*01, DRB1*1301, and DRB1*15 were associated with good responses whereas DRB1*03 (DRB1*0301), DRB1*04, DRB1*07, and DRB1*1302 were associated with poor responses\(^{[47]}\). Furthermore, evaluations of DQB1 alleles showed that DQB1*05
Persons unresponsive to a first series of three injections have been made to improve the efficacy of vaccine. Vaccine is a serious social problem, several attempts have been made to improve the effectiveness of vaccines, suggesting the need for other strategies to induce anti-HBs production in these subjects.

Third generation HB vaccine
New HB vaccines have been developed to improve anti-HBs response in non-responders. Hepagene™, a third generation vaccine containing pre-S1 and pre-S2 proteins in addition to S protein, has been shown to induce anti-HBs in 76% of previously non-responsive individuals[46]. Another third generation HB vaccine, Sci-B-Vac™, was recently shown to induce anti-HBs in 20 of 21 non- or low-responders, with 12 non-responders and all 6 low responders showing a high anti-HBs response (> 100 mIU/mL)[57]. Moreover, the preventive effect of Sci-B-Vac™ has been assessed in newborns[58,59].

Vaccination plus cytokine
Granulocyte-colony stimulating factor: Recently, HB vaccine was administered together with granulocyte-colony stimulating factor (G-CSF) to patients with liver cirrhosis[60]. However, adjuvant G-CSF did not significantly enhance anti-HBs production.

Granulocyte-macrophage colony stimulating factor: The effect of granulocyte-macrophage colony stimulating factor (GM-CSF) on the response to HBV revaccination in non-responders has been evaluated[61]. Although the combination of GM-CSF (150 µg) and HB vaccine (20 µg) induced a higher anti-HBs response than HB vaccine (20 µg) alone, a higher dose (40 µg) of HB vaccine induced a higher response than the combination. GM-CSF was effective in patients with end-stage renal disease[62], but was ineffective during booster vaccination of HIV-infected patients with low anti-HBs antibody titer[63]. Thus, the stimulatory effect of GM-CSF has not yet been determined.

Other adjuvants
Interleukin (IL)-2 was not effective as an adjuvant[64,65]. In contrast, levamisole used as an adjuvant in HB vaccination has shown promising results[66,67]. New chemical adjuvants [AS02(v) and AS04] have also been found to increase response to HB vaccine[68-70].

Intradermal vaccination
HB vaccine is usually given intramuscularly, but intradermal vaccination was shown to be superior[71]. Intradermal vaccination induced higher anti-HBs positivity rates or a similar rate as intramuscular vaccine with smaller doses of vaccine[72]. The ability of intradermal administration to improve the effectiveness of vaccination has been tested, but intradermal vaccination is about 50% of these individuals showing an anti-HBs response[16,54]. Non-responders to the second course should be evaluated for underlying chronic HBV infection. Response in patients on hemodialysis may be improved using double-dose vaccine[55]. However, some individuals are non-responsive to multiple series of vaccinations, suggesting the need for other strategies to induce anti-HBs production in these subjects.

### Table 2 Factors associated with poor response to hepatitis B virus vaccination

| Factors                                                                 |   |
|------------------------------------------------------------------------|---|
| Underlying medical conditions                                         |   |
| Chronic HBV infection                                                  |   |
| Hemodialysis                                                           |   |
| Immature neonates                                                      |   |
| HIV infection                                                          |   |
| Immunosuppressor administration                                       |   |
| Genetic factors                                                        |   |
| HLA haplotypes                                                         |   |
| Celiac disease                                                         |   |
| SNPs (cytokine, chemokine)                                             |   |
| Technical errors                                                       |   |
| Intra-gluteal injection                                                |   |
| Inappropriate storage conditions                                       |   |

SNPs: Single nucleotide polymorphisms; HLA: Human leukocyte antigen; HBV: Hepatitis B virus.

(DQB1*0501), DQB1*06, and DQB1*0602 were associated with good responses, whereas DQB1*02 was associated with poor response[57].

Cytokine and chemokine gene polymorphisms
Associations between single nucleotide polymorphisms (SNPs) at the interleukin (IL)-2 and IL4 loci, along with insertion/deletion variants at the IL12B locus, have been associated with responses to HB vaccines[46]. Moreover, three SNPs (rs497916, rs3922, rs676925) in CXCR5 and one SNP (rs355687) in CXCL13 were associated with response to HB vaccine. These findings indicate that cytokines and chemokines are actively involved in responses to HB vaccine[49].

Regulatory T-cells
The poor responses of HIV-infected patients to HB vaccine were thought to be due to low numbers of CD4+ T cells[50]. However, the percent of regulatory T-cells was found to be negatively associated with response to HB vaccine in HIV-infected patients, suggesting another mechanism for low anti-HBs production in response to HB vaccine[49].

T cell immunoglobulin mucin-domain-3
Hepatitis C virus (HCV)-infected patients have been reported to show a poorer response to HB vaccine than healthy subjects[52]. This may be due to the differential regulation of IL-12/IL-23 production secondary to over-expression of T cell immunoglobulin mucin-domain-3 on monocytes[53].

Attempts to improve the efficacy of HB vaccine:
Because the existence of non-responders to HB vaccine is a serious social problem, several attempts have been made to improve the efficacy of vaccine. Persons unresponsive to a first series of three injections (i.e., anti-HBs < 10 mIU/mL) are recommended to complete a second 3-dose vaccine series, with

**References**

[16,54]...[72]
technically difficult[73].

Intradermal administration every two weeks into non-responders to conventional intramuscular vaccination induced anti-HBs responses in 94% of the subjects[74]. Intradermal vaccination has induced better responses to HB vaccine than conventional intramuscular vaccination in healthcare workers[75,76], dialysis patients[77-79], HIV infected patients[80], and patients with celiac disease[81]. A comprehensive review of the efficacy of intradermal HB vaccination in non-responders found that this method induced a superior response compared with intramuscular vaccination under various conditions[82].

**Booster immunization**

Several studies have shown that the protective effects of HB vaccination may continue for at least 10 to 15 years[83,84] or even beyond 15 years, especially in subjects with a high anti-HBs titer after the initial course of vaccination[85]. Routine booster vaccinations have been regarded as unnecessary, due to the immunological memory acquired after the initial round of HB vaccination[86,87], and booster vaccination of previously vaccinated individuals has shown to result in a rapid increase in anti-HBs antibody[88]. However, the long-term protective effects of HB vaccination have not been fully investigated. Of 6156 high school students vaccinated during infancy, approximately 10% to 25% lost immune responses to HBsAg[86,87]. A recent report showed that 17.8% of vaccinated students born to highly infectious mothers positive for HBeAg became HBsAg-positive, compared with 11.1% of those born to maternal HBsAg-negative (P = 0.014), suggesting that booster vaccination may be needed for complete prevention of HBV infection[41].

Policies regarding booster vaccination vary among countries. In patients on hemodialysis, vaccine-induced antibody protection may persist only at anti-HBs titers above 10 mIU/mL, suggesting that a booster be administered if the antibody level declines to below 10 mIU/mL[89]. A European consensus statement also recommended booster vaccination if antibody concentration declines to below 10 mIU/mL, depending on the risk of exposure to HBV (Table 3)[90].

In liver transplantation, it was shown that 18 out of 23 recipients from isolated anti-HBc-positive donors developed HBV infection after liver transplantation[91], suggesting a recommendation of booster vaccination to acquire anti-HBs levels above 10 mIU/mL in all HBsAg-negative recipients before transplantation even if the donors are negative for HBsAg.

**Escape mutants**

Mutations in the small-S protein, most frequently a glycine to arginine substitution at codon 145 (G145R), have been found in some children born to HBV-infected mothers who were found to be infected despite previous vaccination[92,93]. Viruses containing the G145R mutant have been shown to be infectious in chimpanzees[94]. Other S-gene mutations have been identified in codons 120-147, and these mutations may evade neutralizing anti-HBs and infect vaccinated people[95-97]. In Italy, S-gene mutations, such as G145R, P120S and P127S, have been identified in liver transplant patients and in children born to HBsAg carriers and treated with HB vaccine. Although these mutants have been found in many regions around the world, including Taiwan[95], their prevalence appears to be low and constant, and reductions in the efficacy of HB vaccine have not been observed[97,98]. However, a recent report showed that HBV containing G145R had been transmitted by sexual contact to a subject who had received universal HB vaccination[39]. Recently, a vaccinated individual was found to have developed acute hepatitis B, caused by a vaccine-escape mutant[99]. Mathematical modeling predicted that over 50 years were required before any vaccine-escape mutants become predominant[100]. Continued monitoring is necessary to determine if the prevalence of these mutants is increasing and if the protective efficacy of conventional vaccines is maintained. Strategies for practical application of HB vaccine containing pre-S protein should be investigated.

**Cross-genotype preventive effect in HBV vaccination**

HBV strains have been classified into eight genotypes[101,102], with the prevalence of different genotypes varying geographically[103]. However, infection with an HBV genotype different from the native strain has increased in various regions, resulting in the progressive globalization of HBV infection. For example, infection with HBV genotype A strains from foreign countries and subsequent acute hepatitis are increasing in Japan, in which HBV genotype C is the major strain[104]. Infections of Japanese individuals with non-native strains have mainly occurred in adults through sexual contact[105], and UV has not yet been introduced in Japan (Figure 1). Recombinant vaccines

---

**Table 3 High risk individuals for hepatitis B virus infection and recommendations for booster vaccination**

| Individuals                        | Booster recommendation       |
|------------------------------------|------------------------------|
| Health-care workers                | Single dose if anti-HBs < 10 mIU/mL |
| Men who have sex with men          | Ensure primary vaccination, boosters are unnecessary |
| Persons with multiple sexual partners | Ensure primary vaccination, boosters are unnecessary |
| Injection drug users               | No evidence to support booster vaccinations |
| Patients with hemodialysis         | Additional boosters to maintain anti-HBs > 10 mIU/mL |
| Institutionalized patients         | Not recommended |
| Public safety workers              | Single dose if anti-HBs < 10 mIU/mL |
| Spouse, sexual partners and household members of HBV carriers | Receive primary vaccination, boosters are unnecessary |
| Recipients of liver transplantation | Additional boosters to maintain anti-HBs > 10 mIU/mL |

HBs: Hepatitis B surface antigen.
generated from HBsAg of HBV genotype A2 have been used worldwide. Although these A2-type vaccines were suggested to be effective in preventing non-A2 HBV infection[105], this cross-genotype preventive effect has not been fully investigated. Using an animal model, we recently showed that monoclonal antibodies derived from vaccines with genotype C could prevent infection by HBV genotype A[106]. Further investigations and careful observation are required for cross-genotype prevention of HB vaccine.

FUTURE PERSPECTIVES ON HB VACCINE

Several issues require future resolution

First, 5% to 10% of vaccinated healthy subjects are non-responders, and dialysis patients, HIV-infected patients and patients with celiac disease show poorer response to HB vaccine than healthy subjects. Booster vaccination overcomes the non-response in some of these subjects, but a third generation HB vaccine, intradermal vaccination or vaccination with adjuvants may be more effective. Methods are therefore needed to develop anti-HBs responses in non-responders.

Anti-HBs response gradually decreases after a single course of vaccination. However, there are no standard guidelines for the necessity, timing, or method of booster vaccination under various situations. S-gene mutant HBV may escape from HB vaccination with S-protein alone. To prevent infection and spread of HBV with S-mutation, the effectiveness of third generation HB vaccines containing pre-S proteins in addition to S-protein should be determined.

Several countries have not yet introduced UV. Promotion of UV in these countries is mandatory for global eradication of HBV infection.

The significance of co-administration of HBIG with HB vaccine for prevention of mother-to-infant transmission of HBV needs to be fully evaluated. Although the administration of HBIG was shown to prevent intrauterine transmission of HBV and reduce overt infantile hepatitis[107,108], appropriate randomized control trials should be performed in the future.

CONCLUSION

HBV infection remains a serious problem worldwide, and vaccination is the most effective strategy for primary prevention of the infection. Although UV is needed for global eradication of HBV infection, it has not yet been introduced in many countries, including Japan. Third generation vaccines with pre-S proteins have shown better anti-HBs responses even in non-responders, but data on their efficacy are limited. Third generation HB vaccines may also be effective in preventing infection with HBV containing an S-mutation. Strategies are needed to improve vaccine efficacy in non-responders, whether with new vaccines or adjuvants, or by intradermal vaccination. Moreover, guidelines are needed regarding the necessity, timing and method of booster injection of responders with decreased anti-HBs response.

REFERENCES

1 McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005; 25 Suppl 1: 3-8 [PMID: 16103976 DOI: 10.1055/s-2005-915644]
2 Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107 [PMID: 14996343 DOI: 10.1046/j.1365-2893.2003.00487.x]
3 Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156 [PMID: 11668491 DOI: 10.1002/jic.1440]
4 Leung N. Chronic hepatitis B in Asian women of childbearing age. Hepatol Int 2009; 3 Suppl 1: 24-31 [PMID: 19669243 DOI: 10.1007/s12072-009-9142-1]
5 Xu DZ, Yan YP, Choi BC, Xu QJ, Men K, Zhang JX, Liu ZH, Wang FS. Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study. J Med Virol 2002; 67: 20-26 [PMID: 11920813 DOI: 10.1002/jmv.2187]
6 Bai H, Zhang L, Ma L, Dou XG, Feng GH, Zhao GZ. Relationship of hepatitis B virus infection of placental barrier and hepatitis B
HBV vaccination

Jaffri and colleagues evaluated the effects of telbivudine in late pregnancy to prevent intrauterine transmission of HBV. The study, published in Hepatology, found that telbivudine treatment significantly reduced the risk of vertical transmission of HBV [1].

The study was a randomized, double-blind, placebo-controlled trial conducted in pregnant women with chronic hepatitis B infection. Telbivudine was administered to the mother starting at 24 weeks of gestation until delivery. The results showed a significant reduction in the rate of HBV-positive infants in the telbivudine group compared to the placebo group [2].

The authors concluded that telbivudine treatment in late pregnancy is an effective strategy to prevent HBV transmission from mother to fetus, thereby reducing the burden of HBV infection in newborn infants [3].

References:
1. Jaffri KA, Cattaruzza MS, Bass WM, et al. Telbivudine for the prevention of hepatitis B virus transmission from mother to newborn. N Engl J Med 2013; 368: 1581-1589.
2. Jaffri KA, Cattaruzza MS, Bass WM, et al. Telbivudine for the prevention of hepatitis B virus transmission from mother to newborn. N Engl J Med 2013; 368: 1581-1589.
3. Jaffri KA, Cattaruzza MS, Bass WM, et al. Telbivudine for the prevention of hepatitis B virus transmission from mother to newborn. N Engl J Med 2013; 368: 1581-1589.
The role of HLA on vaccine response in patients from eastern Turkey. Biochim Biophys Acta 2011; 1808: 5790-5799 [PMID: 21247314 DOI: 10.1016/j.bbagen.2011.06.010]

Lai MW, Lin TY, Tsao KC, Huang GC, Hsiao MJ, Liang KH, Yeh CT. Increased seroconversion of HBV DNA with mutations in the E gene among individuals greater than 18 years old after complete vaccination. Gastroenterology 2012; 143: 400-407 [PMID: 22580098 DOI: 10.1053/j.gastro.2012.05.002]

Wu TW, Lin HH, Wang LY. Chronic hepatitis B infection in adolescents who received primary infantile vaccination. Hepatology 2013; 57: 37-45 [PMID: 22858989 DOI: 10.1002/hep.25988]

Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998; 15: 1-8 [PMID: 9651632 DOI: 10.1016/S0749-3797(98)00003-8]

Albayrak A, Ertek M, Tasyaran MA, Pirim I. Role of HLA allele polymorphism in chronic hepatitis B virus infection and HBV vaccine sensitivity in patients from eastern Turkey. Biochem Genet 2011; 49: 258-269 [PMID: 21188490 DOI: 10.1007/s10528-010-9404-6]

Mert G, Sengul A, Gul HC, Karakas A, Egyiun CP. The role of human leukocyte antigen type in hepatitis B virus infection in Turkey. J Microbiol Immunol Infect 2014; 47: 9-14 [PMID: 23523043 DOI: 10.1016/j.jmii.2013.01.004]

Vitaliti G, Pratićo AD, Cimino C, Di Dio G, Lionetti E, La Rosa M, Leonardi S. Hepatitis B virus in cellular disease: yesterday, today, and tomorrow. World J Gastroenterol 2013; 19: 838-845 [PMID: 23430309 DOI: 10.3748/wjg.v19.i6.838]

Yoon JH, Shin S, Jw, Chang JY, Song EY, Roh EY. Association of HLA alleles with the responsiveness to hepatitis B virus vaccination in Korean infants. Vaccine 2014; 32: 5638-5644 [PMID: 25148772 DOI: 10.1016/j.vaccine.2014.08.007]

Li ZK, Nie JJ, Li J, Zhang H. The effect of HLA on immunological response to hepatitis B vaccine in healthy people: a meta-analysis. Vaccine 2013; 31: 4355-4361 [PMID: 23887040 DOI: 10.1016/j.vaccine.2013.06.108]

Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, Kaslow RA. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology 2004; 39: 978-988 [PMID: 15057902 DOI: 10.1002/hep.20142]

Duan Z, Chen X, Liang Z, Zeng Y, Zhu F, Long L, McCrae MA, Zhuang H, Shen T, Lu F. Genetic polymorphisms of CXCR5 and CXCL13 are associated with non-responsiveness to the hepatitis B vaccine. Vaccine 2014; 32: 5316-5322 [PMID: 25077417 DOI: 10.1016/j.vaccine.2014.07.064]

Kim HW, Harrington RD, Van Rompaey SE, Kitahata MM. Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons. AIDS 2008; 19: 600-604 [PMID: 18725550 DOI: 10.1097/QAI.0b013e3282f67197]

del Pozo Balado Mdel M, Leal M, Méndez Lagares G, Mata RC, Mauri JM. Effects of recombinant interleukin-2 and activin A on revaccination in non-responders to hepatitis B vaccination in patients with cirrhosis: a double blind randomized placebo controlled trial. Hepat Mon 2014; 14: e15447 [PMID: 24910704 DOI: 10.5812/ hepatmon.15447]

Lin C, Zhu J, Zheng Y, Chen Y, Wu Z, Chong Y, Gao Z. Effect of GM-CSF in combination with hepatitis B vaccine on revaccination of healthy adult non-responders. J Infect 2010; 60: 264-270 [PMID: 20138189 DOI: 10.1016/j.jinf.2010.01.011]

Fabrizi F, Ganesan SV, Dixit V, Martin P. Meta-analysis: the adjuvant role of granulocyte macrophage-colony stimulating factor on immunological response to hepatitis B virus vaccine in end-stage renal disease. Aliment Pharmacol Ther 2006; 24: 789-796 [PMID: 16918882 DOI: 10.1111/j.1365-2036.2006.03035.x]

Overton ET, Sunkanurapuh S, Klebert M, Royal M, Demarco-Shaw D, Powderly WG, Aberjn JA. GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected Individuals. Open Viral J 2011; 5: 109-113 [PMID: 22043256 DOI: 10.2174/1874357901105010109]

Jungers P, Devillier P, Salomon H, Cerisier JE, Courouce AM. Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine. Lancet 2004; 363: 856-857 [PMID: 17916403 DOI: 10.1016/S0140-6736(04)90289-0]

Mauri JM, Vallès M. Effects of recombinant interleukin-2 and revaccination for hepatitis B in previously vaccinated, non-respondent, chronic uraemic patients. Collaborative Group of Girona. Nephrol Dial Transplant 1997; 12: 729-732 [PMID: 9141002 DOI: 10.1093/ndt/12.4.729]

Fabrizi F, Dixit V, Martin P, Messa P. Hepatitis C virus and the immunological response to hepatitis B virus in dialysis patients: meta-analysis of clinical studies. J Viral Hepat 2011; 18: 871-876 [PMID: 22093033 DOI: 10.1111/j.1365-2893.2011.01459.x]

Alavian SM, Tabataabei SV. Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trials. Clin Ther 2010; 32: 1-10 [PMID: 20171406 DOI: 10.1016/j.clinthera.2010.01.005]

Kong NC, Beran J, Kee SA, Miguel JL, Sánchez C, Bayas JM, Vidella A, de Juans ER, Angulo PA, Balbo-Correas F, de Novales EL, Hamiaux V, Lievens M, Stoffel M. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 2005; 68: 2298-2303 [PMID: 16221232 DOI: 10.1111/j.1523-1755.2005.00689.x]
to hepatitis B vaccine in hemodialysis patients. *Kidney Int* 2008; 73: 856-862 [PMID: 18160963 DOI: 10.1038/sj.ki.5002725]

70 Tieleman CL, Vlasak J, Kosa D, Billoum JO, Verpoorten GA, Mezei I, Ryba M, Peeters PC, Mat O, Jadoul MY, Polakovic V, Dhane M, Tu D, S, Kuriyakose SK, Leyssen M, Houdar SA, Sarquin M. Immunogenicity and safety of an investigational AS02(V)-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: results of two open, randomized, comparative trials. *Vaccine* 2011; 29: 1159-1166 [PMID: 21167859 DOI: 10.1016/j.vaccine.2010.12.009]

71 Yasumura S, Shimizu Y, Yasuyama T, Hiroki O, Okada K, Tsukishiro T, Tsuchida T, Higuchi K, Watanabe A. Intradermal hepatitis B virus vaccination for low- or non-responded health-care workers. *Acta Med Okayama* 1991; 45: 457-459 [PMID: 1838229]

72 Das HS, Sawant P, Shirhatti RG, Vyas K, Vispute S, Dhadphale S, Patrawalla V, Desai N. Efficacy of low dose intradermal hepatitis B vaccine: results of a randomized trial among health care workers. *Trop Gastroenterol* 2002; 23: 120-121 [PMID: 12693152]

73 Fabrizi F, Andruli S, Bacchini G, Corti M, Locatelli F. Intradermal versus intramuscular hepatitis B re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. *Nephrol Dial Transplant* 1997; 12: 1204-1211 [PMID: 9198052 DOI: 10.1093/ndt/12.6.1204]

74 Playford EG, Hogan PG, Bansal AS, Harrison K, Drummond D, Looke DF, Whitby M. Intradermal recombinant hepatitis B vaccine for healthcare workers who fail to respond to intramuscular vaccine. *Infect Control Hosp Epidemiol* 2002; 23: 87-90 [PMID: 12104326 DOI: 10.1086/340212]

75 Levitz RE, Cooper BW, Regan HC. Immunization with high-dose intradermal recombinant hepatitis B vaccine in healthcare workers who failed to respond to intramuscular vaccination. *Infect Control Hosp Epidemiol* 1995; 16: 88-91 [PMID: 7759824 DOI: 10.2307/30140948]

76 Ghebrehawet S, Baxter D, Falconer M, Paver K. Intradermal recombinant hepatitis B vaccination (IDRV) for non-responsive healthcare workers (HCWs). *Hum Vacccin* 2008; 4: 280-285 [PMID: 18392892 DOI: 10.4161/hv.4.4.54567]

77 Fabrizi F, Dixit V, Messa P, Martin P. Intradermal vs intramuscular vaccine against hepatitis B infection in dialysis patients: a meta-analysis of randomized trials. *J Viral Hepat* 2011; 18: 730-737 [PMID: 20891471 DOI: 10.1111/j.1365-2893.2010.01354.x]

78 Barraclough KA, Wiggins KJ, Hawley CM, van Eps CL, Mudge DW, Johnson DW, Whitby M, Carpenter S, Playford EG. Intradermal versus intramuscular hepatitis B vaccination in hemodialysis patients: a prospective open-label randomized controlled trial in nonresponders to primary vaccination. *Am J Kidney Dis* 2009; 54: 95-103 [PMID: 19481320 DOI: 10.1053/ajkd.2009.03.010]

79 Chanchairuja T, Chantaphakul N, Thanwandee T, Ong-Ajyooth J. Vaccination against hepatitis B infection in dialysis patients. *Kidney Int* 2006; 70: S33-S40 [PMID: 17044452]

80 Whitaker MJ, Rouphael NG, Greydanus DE, Davies HD, Chiu HY, Huang LM, Chen CJ, Chen DS, Kuo HS, Huang LM, Lee CY. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. *J Infect Dis* 2008; 197: 1419-1426 [PMID: 18444799 DOI: 10.1086/587695]

81 Jan CF, Huang KC, Chien YC, Greydanus DE, Davies HD, Chiu TY, Huang LM, Chen CJ, Chen DS. Determination of immune memory to hepatitis B vaccination through early booster response in college students. *Hepatology* 2010; 51: 1547-1554 [PMID: 20209603 DOI: 10.1002/hep.23543]

82 Wiström J, Ahlm C, Lundberg S, Säthergren B, Tärnvik A. Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose. *Vaccine* 1999; 17: 2162-2165 [PMID: 10367949 DOI: 10.1016/S0264-410X(99)00012-2]

83 Probst T, Probst A, Lhotta K, Vogel W, König P. Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. *Am J Kidney Dis* 1998; 32: 1042-1045 [PMID: 9856522 DOI: 10.1053/sj.ajkd.2000.21020]

84 Levitz RE, Cooper BW, Regan HC. Immunization with high-dose intradermal recombinant hepatitis B vaccine in healthcare workers who failed to respond to intramuscular vaccination. *Infect Control Hosp Epidemiol* 1995; 16: 89-91 [PMID: 7759824 DOI: 10.2307/30140948]

85 Chanchairuja T, Chantaphakul N, Thanwandee T, Ong-Ajyooth J. Efficacy of intradermal hepatitis B vaccination compared to intramuscular vaccination in hemodialysis patients. *Lancet Infect Dis* 2006; 6: 1382-1384 [PMID: 1693796 DOI: 10.1016/S1473-3099(06)00134-2]

86 Hsu HY, Chang MH, Ni YH, Lin HH, Wang SM, Chen DS. Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis. *Hepatology* 1997; 26: 786-791 [PMID: 9303514 DOI: 10.1002/hep.510260336]

87 Zuckerkan AJ. Effect of hepatitis B virus mutations on efficacy of vaccination. *Lancet* 2000; 355: 1382-1384 [PMID: 10791517 DOI: 10.1016/S0140-6736(00)02132-2]

88 Hsu HY, Chang MH, Ni YH, Chen HL. Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. *Gut* 2004; 53: 1499-1503 [PMID: 15361503 DOI: 10.1136/gut.2003.034223]

89 Hsu HY, Chang MH, Ni YH, Chiang CL, Chen HL, Wu JF, Chen PJ. No increase in prevalence of hepatitis B surface antigen mutant in a population of children and adolescents who were fully covered by universal infant immunization. *J Infect Dis* 2010; 201: 1192-1200 [PMID: 20216030 DOI: 10.1086/651378]

90 Luongo M, Citrelli R, Grotola A, Giotto S, Bernabucci V, Bevini M, Vecchi C, Montagnani G, Villa E. Acute hepatitis B caused by a vaccine-escape HBV strain in vaccinated subject: sequence analysis and therapeutic strategy. *J Clin Virol* 2015; 62: 89-91 [PMID: 25542480 DOI: 10.1016/j.jcv.2014.11.029]
Wilson JN, Nokes DJ, Carman WF. The predicted pattern of emergence of vaccine-resistant hepatitis B: a cause for concern? Vaccine 1999; 17: 973-978 [PMID: 10067705 DOI: 10.1016/S0264-410X(98)00313-2]

Kramvis A, Kew M, François G. Hepatitis B virus genotypes. Vaccine 2005; 23: 2409-2423 [PMID: 15752827 DOI: 10.1016/j.vaccine.2004.10.045]

Miyakawa Y, Mizokami M. Classifying hepatitis B virus genotypes. Intervirology 2003; 46: 329-338 [PMID: 14688448 DOI: 10.1159/000074988]

Kurbanov F, Tanaka Y, Mizokami M. Geographical and genetic diversity of the human hepatitis B virus. Hepatol Res 2010; 40: 14-30 [PMID: 20156297 DOI: 10.1111/j.1872-034X.2009.00601.x]

Matsuura K, Tanaka Y, Hige S, Yamada G, Murawaki Y, Komatsu M, Kuramitsu T, Kawata S, Tanaka E, Iizumi N, Okuse C, Kakumu S, Okanoue T, Hino K, Hiasa Y, Sata M, Maeshiro T, Sugach F, Nojiri S, Joh T, Miyakawa Y, Mizokami M. Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. J Clin Microbiol 2009; 47: 1476-1483 [PMID: 19297602 DOI: 10.1128/JCM.02081-08]

Cassidy A, Mossman S, Olivieri A, De Ridder M, Leroux-Roels G. Hepatitis B vaccine effectiveness in the face of global HBV genotype diversity. Expert Rev Vaccines 2011; 10: 1709-1715 [PMID: 22095174 DOI: 10.1586/erv.11.151]

Hamada-Tsutsui S, Iio E, Watanabe T, Murakami S, Isogawa M, Iijima S, Inoue T, Matsunami K, Tajiri K, Ozawa T, Kishi H, Muraguchi A, Joh T, Tanaka Y. Validation of cross-genotype neutralization by hepatitis B virus-specific monoclonal antibodies by in vitro and in vivo infection. PLoS One 2015; 10: e0118062 [PMID: 25693196 DOI: 10.1371/journal.pone.0118062]

Chen HL, Lin LH, Hu FC, Lee JT, Lin WT, Yang YJ, Huang FC, Wu SF, Chen SC, Wen WH, Chu CH, Ni YH, Hsa HY, Tsai PL, Chang CL, Shyu MK, Lee PI, Chang FY, Chang MH. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology 2012; 142: 773-781.e2 [PMID: 22198276 DOI: 10.1053/j.gastro.2011.12.035]

Shi Z, Li X, Ma L, Yang Y. Hepatitis B immunoglobulin injection in pregnancy to interrupt hepatitis B virus mother-to-child transmission—a meta-analysis. Int J Infect Dis 2010; 14: e622-e634 [PMID: 20106694 DOI: 10.1016/j.ijid.2009.09.008]

P- Reviewer: Chiu KW, Frider B  S- Editor: Qi Y  L- Editor: A  E- Editor: Ma S
